Neoplasms, Squamous Cell
14
1
3
2
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
42.9%
6 terminated out of 14 trials
25.0%
-61.5% vs benchmark
14%
2 trials in Phase 3/4
250%
5 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (14)
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Intended Use Study of the BD SurePath Plus™ Pap
Safety Study of SEA-CD40 in Cancer Patients
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma